Edgewise Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Edgewise Therapeutics, Inc. (EWTX) reported Basic Shares Outstanding (Weighted Average) of 107.67 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 107.67M shares, a 2.60% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 107.12M shares, a 12.60% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 106.05M shares, a 11.94% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 105.49M shares, a 12.45% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 102.93M shares, a 11.38% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 92.41M shares, a 45.02% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 63.72M shares, a 18.90% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 53.59M shares, a 42.82% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 107.67M shares 10-Q · filed 2026-08-06 | 107.39M shares 10-Q · filed 2026-08-06 | 106.94M shares derived: average of 3 quarters · filed 2026-08-06 | 106.58M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 107.12M shares 10-Q · filed 2026-05-07 | 106.58M shares derived: average of 2 quarters · filed 2026-05-07 | 106.22M shares derived: average of 3 quarters · filed 2026-05-07 | 105.90M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 106.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 105.77M shares derived: average of 2 quarters · filed 2026-02-26 | 105.49M shares derived: average of 3 quarters · filed 2026-08-06 | 102.93M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 105.49M shares 10-Q · filed 2025-11-06 | 105.22M shares derived: average of 2 quarters · filed 2026-08-06 | 101.89M shares 10-Q · filed 2025-11-06 | 100.08M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 104.94M shares 10-Q · filed 2026-08-06 | 100.06M shares 10-Q · filed 2026-08-06 | 98.27M shares derived: average of 3 quarters · filed 2026-08-06 | 97.16M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 95.13M shares 10-Q · filed 2026-05-07 | 94.93M shares derived: average of 2 quarters · filed 2026-05-07 | 94.56M shares derived: average of 3 quarters · filed 2026-05-07 | 94.30M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 94.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 94.28M shares derived: average of 2 quarters · filed 2026-02-26 | 94.02M shares derived: average of 3 quarters · filed 2026-02-26 | 92.41M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 93.81M shares 10-Q · filed 2025-11-06 | 93.66M shares derived: average of 2 quarters · filed 2025-11-06 | 91.64M shares 10-Q · filed 2025-11-06 | 84.92M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 93.52M shares 10-Q · filed 2025-08-07 | 90.54M shares 10-Q · filed 2025-08-07 | 81.96M shares derived: average of 3 quarters · filed 2026-02-26 | 77.33M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 87.57M shares 10-Q · filed 2025-05-08 | 76.18M shares derived: average of 2 quarters · filed 2026-02-26 | 71.94M shares derived: average of 3 quarters · filed 2026-02-26 | 69.80M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 64.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 64.12M shares derived: average of 2 quarters · filed 2026-02-26 | 63.88M shares derived: average of 3 quarters · filed 2026-02-26 | 63.72M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 63.46M shares 10-Q · filed 2024-11-07 | 63.42M shares derived: average of 2 quarters · filed 2024-11-07 | 63.37M shares 10-Q · filed 2024-11-07 | 63.36M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 63.38M shares 10-Q · filed 2024-08-08 | 63.32M shares 10-Q · filed 2024-08-08 | 63.33M shares derived: average of 3 quarters · filed 2024-08-08 | 60.46M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 63.27M shares 10-Q · filed 2024-05-09 | 63.30M shares derived: average of 2 quarters · filed 2024-05-09 | 59.48M shares derived: average of 3 quarters · filed 2024-05-09 | 57.02M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 63.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 57.59M shares derived: average of 2 quarters · filed 2024-02-22 | 54.94M shares derived: average of 3 quarters · filed 2024-02-22 | 53.59M shares 10-K · filed 2024-02-22 |
| 2022-09-30 | 51.84M shares 10-Q · filed 2023-11-09 | 50.73M shares derived: average of 2 quarters · filed 2023-11-09 | 50.35M shares 10-Q · filed 2023-11-09 | 50.13M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 49.62M shares 10-Q · filed 2023-08-10 | 49.58M shares 10-Q · filed 2023-08-10 | 49.56M shares derived: average of 3 quarters · filed 2023-08-10 | 49.48M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 49.54M shares 10-Q · filed 2023-05-11 | 49.52M shares derived: average of 2 quarters · filed 2023-05-11 | 49.44M shares derived: average of 3 quarters · filed 2023-05-11 | 49.39M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 49.50M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 49.38M shares derived: average of 2 quarters · filed 2023-02-23 | 49.34M shares derived: average of 3 quarters · filed 2023-02-23 | 37.53M shares 10-K · filed 2023-02-23 |
| 2021-09-30 | 49.26M shares 10-Q · filed 2022-11-03 | 49.26M shares derived: average of 2 quarters · filed 2022-11-03 | 33.54M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 49.26M shares 10-Q · filed 2022-08-04 | 25.54M shares 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 1.56M shares 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 739.00K shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |